نتائج البحث - "Mei Lin Ah-See"

1

Olaparib and durvalumab in patients with relapsed small cell lung cancer (MEDIOLA): An open-label, multicenter, phase 1/2, Basket Study

المؤلفون: Matthew G. Krebs, Jean-Pierre Delord, Thomas R. Jeffry Evans, Maja De Jonge, Sang-We Kim, Marie Meurer, Sophie Postel-Vinay, Jong-Seok Lee, Helen K. Angell, Vidalba Rocher-Ros, Kassondra Meyer, Mei-Lin Ah-See, Pia Herbolsheimer, Zhongwu Lai, Ana Nunes, Susan M. Domchek

المساهمون: Medical Oncology

المصدر: Krebs, M G, Delord, J-P, Jeffry Evans, T R, De Jonge, M, Kim, S-W, Meurer, M, Postel-Vinay, S, Lee, J-S, Angell, H K, Rocher-Ros, V, Meyer, K, Ah-See, M-L, Herbolsheimer, P, Lai, Z, Nunes, A & Domchek, S M 2023, ' Olaparib and durvalumab in patients with relapsed small cell lung cancer (MEDIOLA): An open-label, multicenter, phase 1/2, Basket Study ', Lung Cancer, vol. 180, 107216 . https://doi.org/10.1016/j.lungcan.2023.107216
Lung Cancer, 180:107216. Elsevier Ireland Ltd

مصطلحات موضوعية: Pulmonary and Respiratory Medicine, Cancer Research, PARP inhibitor, Oncology, SDG 3 - Good Health and Well-being, durvalumab, immunotherapy, small cell lung cancer, olaparib

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2f55b6a72887c16967c05c789e2f26d5
https://doi.org/10.1016/j.lungcan.2023.107216

View record from ScienceDirect

Full Text via ClinicalKey

2

دورية أكاديمية

Management of hot flushes in UK breast cancer patients: clinician and patient perspectives

المؤلفون: Deborah Fenlon, Adrienne Morgan, Priya Khambaita, Pankaj Mistry, Janet Dunn, Mei-Lin Ah-See, Emma Pennery, Myra S. Hunter, on behalf of the NCRI CSG Breast Cancer Symptom Working Party

المصدر: Journal of Psychosomatic Obstetrics and Gynecology, Vol 38, Iss 4, Pp 276-283 (2017)

مصطلحات موضوعية: menopause, breast cancer, hot flushes, survey, management, Gynecology and obstetrics, RG1-991

وصف الملف: electronic resource

Relation: https://doaj.org/toc/0167-482X; https://doaj.org/toc/1743-8942

URL الوصول: https://doaj.org/article/9ea7dadf47fc45768c77998a9acf4869

PDF full text from Publisher

3

Overall Survival With Maintenance Olaparib at a 7-Year Follow-up in Patients With Newly Diagnosed Advanced Ovarian Cancer and a BRCA Mutation: The SOLO1/GOG 3004 Trial

المساهمون: Institut Català de la Salut, [DiSilvestro P] Program in Women's Oncology, Women & Infants Hospital, Providence, RI. [Banerjee S] The Royal Marsden NHS Foundation Trust and Institute of Cancer Research, London, United Kingdom. [Colombo N] University of Milan-Bicocca and Istituto Europeo di Oncologia IRCCS, Milan, Italy. [Scambia G] Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy. [Kim BG] Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea. [Oaknin A] Gynaecologic Cancer Programme, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain. Vall d'Hebron Hospital Universitari, Barcelona, Spain, Vall d'Hebron Barcelona Hospital Campus, Disilvestro, P, Banerjee, S, Colombo, N, Scambia, G, Kim, B, Oaknin, A, Friedlander, M, Lisyanskaya, A, Floquet, A, Leary, A, Sonke, G, Gourley, C, Oza, A, González-Martín, A, Aghajanian, C, Bradley, W, Mathews, C, Liu, J, Mcnamara, J, Lowe, E, Ah-See, M, Moore, K

المصدر: Scientia
Disilvestro, P, Banerjee, S, Colombo, N, Scambia, G, Kim, B, Oaknin, A, Friedlander, M, Lisyanskaya, A, Floquet, A, Leary, A, Sonke, G S, Gourley, C, Oza, A, González-martín, A, Aghajanian, C, Bradley, W, Mathews, C, Liu, J, Mcnamara, J, Lowe, E S, Ah-see, M & Moore, K N 2022, ' Overall Survival With Maintenance Olaparib at a 7-Year Follow-Up in Patients With Newly Diagnosed Advanced Ovarian Cancer and a BRCA Mutation: The SOLO1/GOG 3004 Trial ', Journal of Clinical Oncology . https://doi.org/10.1200/JCO.22.01549

مصطلحات موضوعية: Cancer Research, Otros calificadores::/uso terapéutico [Otros calificadores], Neoplasms::Neoplasms by Site::Endocrine Gland Neoplasms::Ovarian Neoplasms [DISEASES], Genetic Phenomena::Genetic Variation::Mutation [PHENOMENA AND PROCESSES], Medicaments antineoplàstics - Ús terapèutic, Otros calificadores::Otros calificadores::/farmacoterapia [Otros calificadores], acciones y usos químicos::acciones farmacológicas::usos terapéuticos::antineoplásicos [COMPUESTOS QUÍMICOS Y DROGAS], Obstetrics and Gynecology, General Medicine, Ovaris - Càncer - Tractament, neoplasias::neoplasias por localización::neoplasias de las glándulas endocrinas::neoplasias ováricas [ENFERMEDADES], Other subheadings::Other subheadings::/drug therapy [Other subheadings], Ovarian Cancer, Olaparib, Settore MED/40 - GINECOLOGIA E OSTETRICIA, Anomalies cromosòmiques, Oncology, SOLO1/GOG 3004 Trial, Other subheadings::/therapeutic use [Other subheadings], Chemical Actions and Uses::Pharmacologic Actions::Therapeutic Uses::Antineoplastic Agents [CHEMICALS AND DRUGS], BRCA Mutation, fenómenos genéticos::variación genética::mutación [FENÓMENOS Y PROCESOS]

وصف الملف: application/pdf; STAMPA

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2c377cbc45ec231613ffe9f64fdb9a33
https://doi.org/10.1097/ogx.0000000000001120

4

LB001/#1731 Late-breaking abstract presentation: overall survival by number of prior lines of chemotherapy in patients with BRCA-mutated platinum-sensitive relapsed ovarian cancer receiving olaparib treatment or non-platinum chemotherapy in SOLO3

المؤلفون: Charles Leath Iii, Giovanni Scambia, Ricardo Villalobos, Nicoletta Colombo, David Cibula, Mariusz Bidziński, Jae-Weon Kim, Joo-Hyun Nam, Radosław Mądry, Carlos Hernandez, Paulo Mora, Sang Young Ryu, Mei-Lin Ah-See, Elizabeth S Lowe, Natalia Lukashchuk, Dave Carter, RT Penson

المصدر: Oral Abstracts (Regular and Late-Breaking Submission).

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_________::3bca3801a0e09c485245f596d2027ddf
https://doi.org/10.1136/ijgc-2022-igcs.1

5

Effect of food on the pharmacokinetics of the WEE1 inhibitor adavosertib (AZD1775) in patients with advanced solid tumors

المؤلفون: Alain Ravaud, Ganesh Mugundu, Liselot Valkenburg-van Iersel, Lone Ottesen, Karen So, Marit A C Vermunt, Fiona C Thistlethwaite, Yan Li, Mariette Labots, Mario Campone, Mats Någård, Patricia Roxburgh, Mei-Lin Ah-See

المساهمون: RS: GROW - R3 - Innovative Cancer Diagnostics & Therapy, MUMC+: MA Medische Oncologie (9), CCA - Cancer biology and immunology, Medical oncology

المصدر: Cancer Chemotherapy and Pharmacology, 86(1), 97-108. Springer Verlag
Någård, M, Ah-See, M-L, So, K, Vermunt, M, Thistlethwaite, F, Labots, M, Roxburgh, P, Ravaud, A, Campone, M, Valkenburg-van Iersel, L, Ottesen, L, Li, Y & Mugundu, G 2020, ' Effect of food on the pharmacokinetics of the WEE1 inhibitor adavosertib (AZD1775) in patients with advanced solid tumors ', Cancer Chemotherapy and Pharmacology, vol. 86, no. 1, pp. 97-108 . https://doi.org/10.1007/s00280-020-04101-4
Cancer Chemotherapy and Pharmacology

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::41b79a45c1b4aa90b1e59f2e5e2bf9ed
https://cris.maastrichtuniversity.nl/en/publications/ceaf7d64-ddd9-4f1c-ab7b-f9010a0a093c

Find this article in full text from Springer Verlag.

Find this article in full text from ProQuest

6

MONO-OLA1: A randomized, phase III study of olaparib maintenance monotherapy in patients with BRCA wild-type advanced ovarian cancer following response to first-line platinum-based chemotherapy (334)

المؤلفون: Valeriya Saevets, Rutie Yin, Jianqing Zhu, Chris Chen, Jing Zhang, Mei-Lin Ah-See, Xiaohua Wu

المصدر: Gynecologic Oncology. 166:S172

مصطلحات موضوعية: Oncology, Obstetrics and Gynecology

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_________::e953ec9cb8aa747804d6c93ddaac3aa6
https://doi.org/10.1016/s0090-8258(22)01556-6

View record from ScienceDirect

Full Text via ClinicalKey

7

Comparison of whole-body MRI, CT, and bone scintigraphy for response evaluation of cancer therapeutics in metastatic breast cancer to bone

المؤلفون: Dow-Mu Koh, Stephanie Sutherland, Mei-Lin Ah-See, Anwar R. Padhani, Peter Ostler, M. Kosmin, Andrea Marshall, Janet A. Dunn, David Woolf, Andrew Gogbashian, Jillian Noble, David Miles, Andreas Makris

مصطلحات موضوعية: medicine.medical_specialty, Bone disease, Contrast Media, Bone Neoplasms, Breast Neoplasms, 030218 nuclear medicine & medical imaging, RC0254, 03 medical and health sciences, 0302 clinical medicine, McNemar's test, Image Interpretation, Computer-Assisted, medicine, Humans, Whole Body Imaging, Radiology, Nuclear Medicine and imaging, Prospective Studies, Radionuclide Imaging, Prospective cohort study, medicine.diagnostic_test, business.industry, Cancer, Magnetic resonance imaging, Middle Aged, medicine.disease, Magnetic Resonance Imaging, Metastatic breast cancer, Bone scintigraphy, 030220 oncology & carcinogenesis, Female, Radiology, Radiopharmaceuticals, Tomography, X-Ray Computed, business, Progressive disease

وصف الملف: application/pdf

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b65c878f9a3d0dafdde59c9433004d98
http://wrap.warwick.ac.uk/143637/1/WRAP-Comparison-whole-body-MRI-CT-bone-Marshall-2020.pdf

8

6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE) : 4-year disease-free survival results of a randomised phase 3 non-inferiority trial

المؤلفون: Jane Brown, Roshan Agarwal, Catherine Harper-Wynne, A. Humphreys, Eliot Sims, Peter Hall, Mukesh Mukesh, Sundus Yahya, Nawaz Walji, Mojca Persic, Donna L. Howe, Simon Waters, Wendy Taylor, Anita Chhabra, Karen Tipples, Helen Innes, Mark Churn, Peter Ostler, Pamela Woodings, Helen Roe, Lisa H Barraclough, Shrushma Loi, Maggie Wilcox, Susan Lupton, Adrian Harnett, Rebecca Bowen, Peter Simmonds, Natasha Mithal, H. M. Earl, Apurna Jegannathen, Kathryn Wright, A.S. Dhadda, Rozenn Allerton, Jean Abraham, Karen McAdam, Ioannis Gounaris, Mohini Varughese, Mark Harries, Helen Neville-Webbe, Catherine Bale, Narottam Thanvi, Carolyn Bedi, Carlos Caldas, Fharat A. Raja, Helena M. Earl, David Miles, Trevor McGolick, Andrew D. Goodman, Kerry Raynes, Anthony Neal, Richard Simcock, Hartmut Kristeleit, Carol MacGregor, Christopher McCabe, Caroline Archer, Laura Pettit, Chris Bradley, Anne-Laure Vallier, Urmila Barthakur, Perric Crellin, S O'Reilly, Betania Mahler Araujo, Andrew Eichholz, Louise Hiller, Anne Rigg, Janine Mansi, Jacqueline Newby, Janet A. Dunn, Sarah Smith, Chris Plummer, Jennifer Marshall, Aian Moss, Zafar Malik, Larry Hayward, Mohammad Butt, Andrew M Wardley, Anup Vinayan, Shiroma De Silva-Minor, Mei-Lin Ah-See, Sue Down, Helen B Higgins, Catherine Reed, Kim Benstead, Rakesh Mehra, Luke Hughes-Davies, David Cameron, Daniel Nelmes, O.S. Din, Charlotte Moss, Daniel Epurescu, Anne C Armstrong, Nicola Storey, David J. Eaton, Hafiz Algurafi, Mariam Jafri, Daniel Rea, Nihal Shah, Elena Provenzano, Susan Cleator, Muireann Kelleher, Claire Hulme, Daniela Lee, D. Bloomfield, Margaret Daly, Joanne Cliff, Chee Goh, Sanjay Raj, Maher Hadaki, Jayant S. Vaidya, Robert Grieve

المساهمون: PERSEPHONE Steering Committee and Trial Investigators

المصدر: Earl, H M, Hiller, L, Vallier, A-L, Loi, S, McAdam, K, Hughes-Davies, L, Harnett, A N, Ah-See, M-L, Simcock, R, Rea, D, Raj, S, Woodings, P, Harries, M, Howe, D, Raynes, K, Higgins, H B, Wilcox, M, Plummer, C, Mansi, J, Gounaris, I, Mahler-Araujo, B, Provenzano, E, Chhabra, A, Abraham, J E, Caldas, C, Hall, P S, McCabe, C, Hulme, C, Miles, D, M Wardley, A & Cameron, D A & Dunn, J A 2019, ' 6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial ', The Lancet, vol. 393, no. 10191, pp. 2599-2612 . https://doi.org/10.1016/S0140-6736(19)30650-6
Lancet (London, England)